Endurant Capital Management LP Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Endurant Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $1.28 Million - $2.25 Million	-15,400 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $1.03 Million - $1.33 Million	9,331 Added 153.75%	15,400 $1.83 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $605,261 - $901,125	6,069 New	6,069 $836,000
Q2 2019 Aug 14, 2019	SELL	$39.79 - $67.01 $297,589 - $501,167	-7,479 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$34.52 - $53.29 $258,175 - $398,555	7,479 New	7,479 $385,000

Q1 2018 May 15, 2018	SELL	$22.49 - $34.56 $231,646 - $355,968	-10,300 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$20.44 - $35.56 $210,532 - $366,268	10,300	10,300 $278,000

565K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.45B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.